Basics BioCryst Pharmaceuticals, Inc. Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases. IPO Date: March 4, 1994 Sector: Healthcare Industry: Biotech Market Cap: $2.26B Activated in VL: True Average Daily Range Avg Daily Range: $0.21 | 3.07% Avg Daily Range (30 D): $0.24 | 2.53% Avg Daily Range (90 D): $0.20 | 2.37% Institutional Daily Volume Avg Daily Volume: 1.51M Avg Daily Volume (30 D): 5.06M Avg Daily Volume (90 D): 3.69M Trade Size Avg Trade Size (Sh.): 181 Avg Trade Size (Sh.) (30 D): 140 Avg Trade Size (Sh.) (90 D): 138 Institutional Trades Total Inst.Trades: 3,612 Avg Inst. Trade: $2.24M Avg Inst. Trade (30 D): $3.65M Avg Inst. Trade (90 D): $2.96M Avg Inst. Trade Volume: .27M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.09M Avg Closing Trade (30 D): $4.62M Avg Closing Trade (90 D): $3.29M Avg Closing Volume: 376.18K         News May 16, 2025 @ 11:00 AM BioCryst Presents New Real-world Evidence Showing ... Source: N/A May 2, 2025 @ 11:00 AM BioCryst Reports Inducement Grants Under Nasdaq Li... Source: N/A Apr 30, 2025 @ 11:00 AM BioCryst to Present at Upcoming Investor Conferenc... Source: N/A Apr 4, 2025 @ 11:00 AM BioCryst Reports Inducement Grants Under Nasdaq Li... Source: N/A Apr 2, 2025 @ 8:01 PM BioCryst to Present at Upcoming Investor Conferenc... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.26 $ $-.13 Diluted EPS $-.26 $ $-.13 Revenue $ 503.49M $ 145.53M $ 131.53M Gross Profit $ 487.91M $ 140.97M $ 125.44M Net Income / Loss $ -53.47M $ .03M $ -26.8M Operating Income / Loss $ 33.17M $ 21.23M $ -4.51M Cost of Revenue $ 15.57M $ 4.57M $ 6.09M Net Cash Flow $ 20.75M $ .56M $ 7.26M PE Ratio